Pharmacological management of COPD

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Respiratory Diseases

Background:

• Pharmacological management of chronic obstructive pulmonary disease (COPD) prioritizes symptom alleviation and exacerbation prevention.
• Inhaled therapies, including combination inhalers with long-acting bronchodilators and inhaled corticosteroids (ICS), are standard for COPD treatment.
• Personalized approaches, such as using blood eosinophil counts to guide ICS therapy, are increasingly important.

Purpose of the Study:

• To review recent advancements in COPD pharmacology.
• To cover novel molecules, emerging evidence, and evolving clinical practices in COPD management.

Main Methods:

• Review of current literature on COPD pharmacological treatments.
• Analysis of clinical trial data for new therapeutic agents.
• Examination of changes in clinical practice guidelines.

Main Results:

• Combination inhalers offer practical advantages and are widely used based on clinical evidence.
• Blood eosinophil counts aid in personalizing inhaled corticosteroid (ICS) therapy for COPD patients.
• Biological treatments, including dupilumab and ensifentrine, show promise in clinical trials for COPD.

Conclusions:

• Novel pharmacological agents like dupilumab and ensifentrine represent significant progress in COPD treatment.
• Future COPD management will likely incorporate a precision medicine approach with biological therapies.
• Continued research and evidence are crucial for refining COPD pharmacological strategies.